Jun 2026 (Q2 FY26) — Aug 4, 2026
Niagen Bioscience Q2 FY26 — Platform Evolution and Strategic Growth
Read the full callNiagen Bioscience (NAGE) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Niagen Bioscience earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 29.8 | −4.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 2.4 | −7.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 0.96 | −73.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$2.5 +0.40% · +$0.01
Performance −65.9% 1Y
1Y: $7.33 on 17 Oct 2025 → $2.5. High $7.6 (27 Oct 2025), low $2.49 (16 Oct 2026).
- Previous close
- $2.49
- 52-week range
- $2.49 – $7.6
- One year
- −65.33%
Overview
- Symbol
- NAGE
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Niagen Bioscience earnings calls (NAGE)
Financials
What the filings say
Net profit, year on year: −73% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 26 | 29 | 30 | 31 | 34 | 34 | 31 | 30 |
| Operating profit | 2 | 7 | 5 | 3 | 4 | 4 | 2 | 1 |
| Operating margin | 6.3% | 24.4% | 15.7% | 10.2% | 12.5% | 12.1% | 5.0% | 2.4% |
| Profit before tax | 2 | 7 | 5 | 4 | 5 | 4 | 7 | 1 |
| Tax rate | 0.0% | 4.1% | 3.2% | 3.4% | 4.6% | 6.6% | 6.2% | 9.9% |
| Net profit | 2 | 7 | 5 | 4 | 5 | 4 | 6 | 1 |
| EPS ($ per share) | 0.02 | — | 0.07 | 0.05 | 0.06 | — | 0.08 | 0.01 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -90 | -122 | -142 | -169 | -185 | -190 | -182 | -165 |
| Total liabilities | 15 | 20 | 22 | 26 | 25 | 27 | 22 | 30 |
| Fixed assets | 4 | 4 | 3 | 3 | 3 | 2 | 2 | 1 |
| Total assets | 42 | 40 | 38 | 58 | 54 | 55 | 68 | 106 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -21 | -20 | -11 | -24 | -15 | 7 | 12 | 14 |
| Cash from investing | -2 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Cash from financing | -0 | 17 | 9 | 36 | 8 | -0 | 5 | 7 |
| Net cash flow | — | — | -2 | 12 | -8 | 7 | 17 | 20 |
| Capital expenditure | -1 | -1 | — | — | — | — | — | — |
| Free cash flow | -22 | -21 | — | — | — | — | — | — |
Insider filings
6 filings between Nov 14, 2025 and Jun 30, 2026.
Open market
decisions to buy or sellPurchases
$45.6K
2 purchases by 1 insider
Sales
None
No insider sold shares.
Compensation
not trading decisions- 3
- Award — granted as compensation
- 1
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Pamir Ozan | $45.6K | — | Nov 14, 2025 |
Latest filings (11)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 30, 2026 | Fried Robert N Chief Executive Officer | Award | 1,106 | $3.0K |
| Jun 30, 2026 | Pamir Ozan Chief Financial Officer | Award | 4,255 | $11.5K |
| Jun 30, 2026 | Lopez Carlos Luis SVP, General Counsel | Award | 2,314 | $6.3K |
| Apr 24, 2026 | Fried Robert N Chief Executive Officer | Option exercise | 20,000 | $52.2K |
| Nov 14, 2025 | Pamir Ozan Chief Financial Officer | Purchase | 4,465 | $30.4K |
| Nov 14, 2025 | Pamir Ozan Chief Financial Officer | Purchase | 2,220 | $15.2K |
| Apr 9, 2025 | Fried Robert N Chief Executive Officer | Option exercise | 66,667 | $220.0K |
| Mar 7, 2025 | Lopez Carlos Luis SVP, General Counsel | Purchase | 273 | $2.1K |
| Dec 13, 2024 | Jaksch Frank L Jr Director | Option exercise | 50,001 | $183.0K |
| Dec 13, 2024 | Jaksch Frank L Jr Director | Sale | 37,161 | $230.0K |
| Nov 22, 2024 | Pamir Ozan Chief Financial Officer | Purchase | 2,907 | $21.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Niagen Bioscience, Inc.
Free account. Everything above stays public.
Write why you follow Niagen Bioscience, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading